Does pravastatin promote cancer in elderly patients? A meta-analysis
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
BACKGROUND: An increase in the incidence of cancer among elderly people assigned to pravastatin therapy has been reported in a randomized controlled trial; however, this finding has been attributed to chance. Our aim was to assess the effect of pravastatin therapy on cancer risk and to examine whether the effect varies according to age by performing a detailed meta-analysis and meta-regression analysis of randomized controlled trials. METHODS: We performed a comprehensive literature search for relevant studies published before February 2006. Before analysis, the selected studies were evaluated for publication bias and heterogeneity. Pooled relative risk estimates with 95% confidence intervals (CIs) were calculated using fixed-and random-effects models. Meta-regression analysis was performed to examine the impact of age on the study estimates of the relative risk of cancer due to pravastatin therapy. RESULTS: Twelve trials that investigated the use of pravastatin therapy for cardiovascular outcomes were included in the analysis (n = 42 902). Although the overall association between pravastatin use and cancer was not statistically significant in the fixed-effects (risk ratio [RR] 1.06, 95% CI 0.99 - 1.13) or random-effects model (RR 1.06, 95% CI 0.97 - 1.14), the meta-regression analysis showed that the age of study participants significantly modified the effect of pravastatin therapy on cancer risk (p = 0.006). Specifically, this analysis showed that pravastatin therapy was associated with an increasing risk of cancer as age increased. This finding was remarkably robust in the sensitivity analysis. INTERPRETATION: Our findings suggest an association between pravastatin therapy and cancer in elderly patients. However, given the importance of this potential association, further verification is warranted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Publication bias in clinical research
Easterbrook, P. J., Gopalan, R., Berlin, J. A., & Matthews, D. R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90201-y · Cited by 3,109
The Hazards of Scoring the Quality of Clinical Trials for Meta-analysis
Jüni, P. (1999) · JAMA · doi:10.1001/jama.282.11.1054 · Cited by 1,981 · cited 1×
“Quality scores constructed in an ad hoc fashion may lack validity, and the results may not be associated with the quality of the studies.(10,11) Instead, we performed several subgroup and sensitivity analyses.”
MethodQUANTITATIVE METHODS IN THE REVIEW OF EPIDEMIOLOGIC LITERATURE1
GREENLAND, S. (1987) · Epidemiologic Reviews · doi:10.1093/oxfordjournals.epirev.a036298 · Cited by 1,644
Publication bias: the case for an international registry of clinical trials.
Simes, R. J. (1986) · Journal of Clinical Oncology · doi:10.1200/jco.1986.4.10.1529 · Cited by 747
Hebert, P. R. (1997) · JAMA · doi:10.1001/jama.1997.03550040069040 · Cited by 740
Invited commentary: a critical look at some popular meta-analytic methods
Greenland, S. (1994) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a117248 · Cited by 511
Sterling, T. D., Rosenbaum, W. L., & Weinkam, J. J. (1995) · The American Statistician · doi:10.1080/00031305.1995.10476125 · Cited by 453
Hunt, D., Young, P., Simes, J., Hague, W., Mann, S., Owensby, D., Lane, G., Tonkin, A., & for the LIPID Investigators (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-10-200105150-00007 · Cited by 226 · cited 2×
“cancer incidence by age group).(6) We obtained an estimate that was statistically significantly different from zero for the regression coefficient of the log risk ratio on mean age of study participants (coefficient 0.”
BackgroundMethodFriedenreich, C. M., Brant, R. F., & Riboli, E. (1994) · Epidemiology · doi:10.1097/00001648-199401000-00011 · Cited by 81 · cited 1×
“Instead, we performed several subgroup and sensitivity analyses.(12) Both of us extracted the data independently.”
Method
Cited by
Statin Adverse Effects: A Review of the Literature and Evidence for a Mitochondrial Mechanism
Golomb, B. A., & Evans, M. A. (2008) · American Journal of Cardiovascular Drugs · doi:10.2165/0129784-200808060-00004 · Cited by 677
Understanding heterogeneity in meta-analysis: the role of meta-regression
Baker, W. L., Michael White, C., Cappelleri, J. C., Kluger, J., Coleman, C. I., & From the Health Outcomes, P. (2009) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02168.x · Cited by 492
Statins and cancer: A systematic review and meta-analysis
Kuoppala, J., Lamminpää, A., & Pukkala, E. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.06.025 · Cited by 285
Rimpelová, S., Kolář, M., Strnad, H., Ruml, T., Vítek, L., & Gbelcová, H. (2021) · Molecules · doi:10.3390/molecules26123528 · Cited by 8
“The findings of the meta-analyses suggested an association between pravastatin treatment and cancer in elderly patients [27] but did not support the potential role of statins in the prevention of hematological malignancies [28] or the hypothesis that statins reduce the risk of pancreatic cancer development [29].”
Result
Metadata
- Authors
- Bonovas, S., & Sitaras, N. M.
- Venue
- Canadian Medical Association Journal
- Publisher
- CMA Joule Inc.
- Published
- 2007-02-07
- Volume
- 176
- Issue
- 5
- Pages
- 649-654
- ISSN
- 0820-3946 (ISSN-L)
- 1488-2329
- OpenAlex
- W2041039344
- Cited by
- 55
- References
- 10
- FWCI
- 0.31
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.